Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Lal

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 2019
Terminal Effector CD8 T Cells Defined by an IKZF2<sup>+</sup>IL-7R<sup>-</sup> Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular CytotoxicityProssy Naluyima, Kerri G Lal, Margaret C Costanzo, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Nature Immunology|October 30, 2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsVincent Dussupt, Rajeshwer S Sankhala, Letzibeth Mendez-Rivera, et al.
Nature Communications|January 3, 2024
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaquesRajeshwer S Sankhala, Kerri G Lal, Jaime L Jensen, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2021
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman PrimatesMichael G Joyce, Hannah A D King, Ines Elakhal Naouar, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 2, 2021
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaquesHannah A D King, M Gordon Joyce, Ines Lakhal-Naouar, et al.
Biorxiv : the Preprint Server for Biology|April 14, 2021
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaquesHannah A D King, M Gordon Joyce, Ines Elakhal Naouar, et al.
Science Translational Medicine|December 16, 2021
A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primatesM Gordon Joyce, Hannah A D King, Ines Elakhal-Naouar, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 2019
Terminal Effector CD8 T Cells Defined by an IKZF2<sup>+</sup>IL-7R<sup>-</sup> Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular CytotoxicityProssy Naluyima, Kerri G Lal, Margaret C Costanzo, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Nature Immunology|October 30, 2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsVincent Dussupt, Rajeshwer S Sankhala, Letzibeth Mendez-Rivera, et al.
Nature Communications|January 3, 2024
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaquesRajeshwer S Sankhala, Kerri G Lal, Jaime L Jensen, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2021
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman PrimatesMichael G Joyce, Hannah A D King, Ines Elakhal Naouar, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 2, 2021
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaquesHannah A D King, M Gordon Joyce, Ines Lakhal-Naouar, et al.
Biorxiv : the Preprint Server for Biology|April 14, 2021
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaquesHannah A D King, M Gordon Joyce, Ines Elakhal Naouar, et al.
Science Translational Medicine|December 16, 2021
A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primatesM Gordon Joyce, Hannah A D King, Ines Elakhal-Naouar, et al.
Pageof 6